Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials
Crossref DOI link: https://doi.org/10.1007/s10067-018-4299-4
Published Online: 2018-09-22
Published Print: 2019-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Feng http://orcid.org/0000-0002-3269-7530
Luo, Zu-chun
Text and Data Mining valid from 2018-09-22
Article History
Received: 5 June 2018
Revised: 22 August 2018
Accepted: 13 September 2018
First Online: 22 September 2018
Compliance with ethical standards
:
: None.